AL
ALKS.US Alkermes Plc
- Market cap
- USD 7.90B
- P/E
- -
- P/B
- 4.23x
- ROE
- -3.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALKS.US undervalued?
Graham numberThe Graham number of Alkermes Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alkermes Plc fundamental analysis
No fundamental analysis for Alkermes Plc yet.
Alkermes Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neu…
Full company profileAlkermes Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alkermes Plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 746M | 903M | 1.09B | 1.17B | 1.04B | 1.17B | 1.11B | 1.66B | 1.56B | 1.48B | 1.83B |
| Gross Profit | 614M | 749M | 918M | 991M | 860M | 976M | 894M | 1.41B | 1.31B | 1.28B | 1.49B |
| Operating Income | -209M | -148M | -99.1M | -175M | -112M | 97.7M | -6.09M | 414M | 421M | 254M | 8.16M |
| EBITDA | -105M | -32.7M | -7.87M | -103M | -6.02M | 178M | 59.8M | 519M | 495M | 331M | 136M |
| Net Income | -208M | -158M | -139M | -197M | -111M | -48.2M | -158M | 356M | 367M | 242M | -66.3M |
| EPS | -1.38 | -1.03 | -0.90 | -1.25 | -0.70 | -0.30 | -0.97 | 2.10 | 2.17 | 1.43 | -0.38 |
| Balance Sheet | |||||||||||
| Total Assets | 1.73B | 1.80B | 1.83B | 1.81B | 1.95B | 2.02B | 1.96B | 2.14B | 2.06B | 2.49B | 4.44B |
| Total Liabilities | 517M | 594M | 654M | 720M | 883M | 912M | 920M | 934M | 591M | 668M | 2.57B |
| Shareholders' Equity | 1.21B | 1.20B | 1.17B | 1.09B | 1.07B | 1.11B | 1.04B | 1.20B | 1.46B | 1.82B | 1.86B |
| Cash & Short-term Investments | 619M | 591M | 539M | 535M | 635M | 536M | 608M | 773M | 752M | 588M | 755M |
| Total Debt | 284M | 281M | 279M | 291M | 410M | 416M | 379M | 372M | 75.5M | 70.0M | 1.57B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -63.8M | 19.2M | 99.3M | 72.1M | 82.8M | 102M | 21.0M | 401M | 439M | 521M | 97.2M |
| Capital Expenditure | 43.7M | 51.3M | 69.4M | 90.9M | 42.2M | 29.0M | 38.3M | 48.0M | 33.5M | 40.4M | 20.9M |
| Free Cash Flow | -107M | -32.1M | 29.9M | -18.9M | 40.6M | 72.7M | -17.2M | 353M | 406M | 480M | 76.4M |
| Ratios | |||||||||||
| ROE | -17.2% | -13.1% | -11.9% | -18.1% | -10.4% | -4.3% | -15.2% | 29.6% | 25.1% | 13.3% | -3.6% |
| ROA | -12.1% | -8.8% | -7.6% | -10.9% | -5.7% | -2.4% | -8.1% | 16.7% | 17.9% | 9.7% | -1.5% |
| Net Profit Margin | -28.0% | -17.5% | -12.7% | -16.8% | -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% | -3.6% |
| Debt to Equity | 0.23x | 0.23x | 0.24x | 0.27x | 0.38x | 0.37x | 0.36x | 0.31x | 0.05x | 0.04x | 0.84x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alkermes Plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 1.43M | 0.01 | - |
| 2021 | USD 8.75M | 0.05 | - |
| 2020 | USD 672K | 0.00 | - |
| 2019 | USD 9.61M | 0.06 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on May 15, 2000.
Who owns Alkermes Plc
- Insiders 1.40%
- Institutions 98.60%
- Public & others 0.00%
- Shares outstanding 168M
- Free float 155M
Top funds holding ALKS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 10.1M | 6.00% | -0.06% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.31M | 3.16% | -0.02% | Sep 2026 |
| iShares Russell 2000 ETF | 4.25M | 2.53% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 3.77M | 2.25% | -1.60% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.49M | 2.08% | +2.68% | Oct 2026 |
| First Trust NYSE Arca Biotech ETF | 2.41M | 1.43% | 0.00% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 2.10M | 1.25% | -4.45% | Sep 2026 |
| Fidelity Small Cap Index | 1.84M | 1.09% | +0.15% | Aug 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 1.53M | 0.91% | -0.05% | Oct 2026 |
| Vanguard Capital Opportunity Inv | 1.52M | 0.91% | -11.29% | Sep 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 1.51M | 0.90% | -0.20% | Oct 2026 |
| iShares Biotechnology ETF | 1.27M | 0.75% | -0.39% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 1.26M | 0.75% | -0.38% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 1.07M | 0.63% | -0.92% | Sep 2026 |
| Invesco S&P SmallCap Momentum ETF | 1.06M | 0.63% | 0.00% | Oct 2026 |
| American Century Small Cap Growth Inv | 993K | 0.59% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 975K | 0.58% | +1.13% | Sep 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 956K | 0.57% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 892K | 0.53% | +0.24% | Oct 2026 |
| T. Rowe Price New Horizons | 888K | 0.53% | +11.12% | Sep 2026 |
Top institutions holding ALKS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 29.2M | 17.40% | +3.25% | Jun 2026 |
| Baker Bros Advisors LP | 10.0M | 5.96% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 9.49M | 5.65% | -0.21% | Jun 2026 |
| State Street Corp | 9.16M | 5.45% | -3.22% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.52M | 4.47% | +1.18% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 6.74M | 4.01% | +44.44% | Jun 2026 |
| Renaissance Technologies Corp | 6.46M | 3.84% | +4.88% | Jun 2026 |
| Geode Capital Management, LLC | 4.48M | 2.66% | +7.07% | Jun 2026 |
| Deep Track Capital, LP | 4.00M | 2.38% | +11.41% | Jun 2026 |
| American Century Companies Inc | 3.95M | 2.35% | -34.88% | Jun 2026 |
| Holocene Advisors, LP | 3.60M | 2.14% | +55.42% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.15M | 1.88% | -24.87% | Sep 2026 |
| COMMODORE CAPITAL LP | 3.00M | 1.79% | -28.57% | Jun 2026 |
| Wellington Management Company LLP | 2.81M | 1.68% | -5.23% | Jun 2026 |
| PRIMECAP Management Company | 2.53M | 1.50% | -0.45% | Jun 2026 |
| First Trust Advisors L.P. | 2.42M | 1.44% | -18.45% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.34M | 1.39% | +4.40% | Jun 2026 |
| Nuveen, LLC | 2.32M | 1.38% | -5.54% | Jun 2026 |
| NORGES BANK | 2.16M | 1.28% | +10.85% | Jun 2026 |
| Bvf Inc | 2.15M | 1.28% | +7.74% | Jun 2026 |
Alkermes Plc company profile
- Company name
- Alkermes Plc
- Ticker
- ALKS.US
- Exchange
- USA Stocks
- Listed since
- Jul 16, 1991
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,050
- Fiscal year end
- December
- Address
- Connaught House, Dublin, Ireland, D04 C5Y6
- Phone
- 353 1 772 8000
- Website
- alkermes.com
About Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes Plc management
10- Mr. Blair C. JacksonPresident, CEO & Director · born 1973
- Mr. Joshua Reed M.B.A.Senior VP & CFO · born 1973
- Mr. David Joseph Gaffin J.D.Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary · born 1972
- Dr. Craig C. Hopkinson M.D.Executive VP of Research & Development and Chief Medical Officer · born 1969
- Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer · born 1970
- Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance · born 1975
- Mr. Tom SkoffSVP & Chief Information Officer
- Ms. Sandra CoombsSenior Vice President of Corporate Affairs & Investor Relations
- Mr. Stephen SchiavoSenior VP & Chief Human Resources Officer
- Mr. Peter NormanSVP of Policy, Government & Community Relations